Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Mitchell

Anesthesiology Lafayette, LA Medical Doctor

NPI 1780671842 CMS profile 1068821

1103 Kaliste Saloom Rd, Suite 304, Lafayette, LA 70508

Open in the dashboard

General payments

$4,523

131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Mitchell of Lafayette, LA is reported in the CMS Open Payments database as having received $4,523 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $359 8
2024 General $461 12
2023 General $379 11
2022 General $176 7
2021 General $700 25
2020 General $1,845 31
2019 General $603 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Mitchell
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Matthew Mitchell were reported at $359. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Matthew Mitchell Anesthesiology median Middle half National median
2019 $603 $72 $23–$151 $163
2020 $1,845 $36 $17–$120 $114
2021 $700 $49 $21–$135 $132
2022 $176 $52 $22–$144 $149
2023 $379 $53 $23–$143 $160
2024 $461 $55 $25–$150 $164
2025 $359 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,716 61 payments
  2. Nevro Corp. $273 9 payments
  3. Medtronic USA, Inc. $258 20 payments
  4. Boston Scientific Corporation $230 4 payments
  5. Pacira Pharmaceuticals Incorporated $217 2 payments
  6. Medtronic, Inc. $150 7 payments
  7. Saluda Medical Americas, Inc. $128 2 payments
  8. BIOTRONIK NRO, Inc. $122 2 payments
  9. Globus Medical, Inc. $50 2 payments
  10. IBSA Pharma Inc. $41 2 payments
  11. Other $339 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,517 127 payments
  2. Travel and Lodging $1,006 4 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $1,037 24 payments
  2. Proclaim IPG Neuromodulation $715 2 payments
  3. Proclaim IPG Neuromodulation $376 10 payments
  4. INTELLIS $258 20 payments
  5. Exparel $217 2 payments
  6. Senza Spinal Cord Stimulation System $184 7 payments
  7. ETERNA $141 1 payment
  8. Intracept $129 1 payment
  9. Evoke $128 2 payments
  10. Prospera $122 2 payments
  11. Other $1,268 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

6,869

Median for Anesthesiology: 322

Drug cost

$159,460

Median for Anesthesiology: $8,738

Branded share of claims

35.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,409 $31,611
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 799 $24,198
Belbuca Buprenorphine Hcl Brand 21 $20,218
Movantik Naloxegol Oxalate Brand 37 $14,917
Tizanidine Hcl Generic 658 $10,212
Gabapentin Generic 788 $9,874
Pregabalin Generic 387 $9,464
Oxycontin Oxycodone Hcl Brand 11 $5,302
Fentanyl Generic 33 $5,080
Baclofen Generic 365 $3,362

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
$95 — —
MOVANTIK
$35 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record